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PARALLEL OPPOSED EDITORIAL

Three discipline collaborative radiation therapy (3DCRT)
special debate: The United States should build additional
proton therapy facilities
1 | THREE DISCIPLINE COLLABORATIVE
RADIATION THERAPY (3DCRT) DEBATE

radiation oncologist at the University of San Francisco – California
specializing in the treatment of pediatric and adult primary and
metastatic brain and spine tumors. His research focus includes exam-

Radiation Oncology is a highly multidisciplinary medical specialty,

ination of late toxicity in patients undergoing radiotherapy using

drawing signiﬁcantly from three scientiﬁc disciplines – medicine, phy-

advanced imaging and clinical analytics toward identiﬁcation of pre-

sics, and biology. As a result, discussion of controversies or changes

dictors and mitigation of cognitive impairment and secondary malig-

in practice within radiation oncology involves input from all three

nancies.

disciplines. For this reason, signiﬁcant effort has been expended

Dr. Wang, is an Assistant Professor at the University of Texas

recently to foster collaborative multidisciplinary research in radiation

MD Anderson Cancer Center. Her research focuses on radiobiology

oncology, with substantial demonstrated beneﬁt.1,2 In light of these

and radio‐sensitization of tumors of the upper aero‐digestive tract,

results, we endeavor here to adopt this “team‐science” approach to

and assessing the preclinical effects of targeted combination treat-

the traditional debates featured in this journal. This article represents

ments both in vitro and in vivo. Her recent emphasis includes the

the ﬁrst in a series of special debates entitled “Three Discipline Col-

biological effects of proton vs photon radiotherapy, including relative

laborative Radiation Therapy (3DCRT)” in which each debate team

biological effectiveness, gene expressions, and cell death mecha-

will include a radiation oncologist, medical physicist, and radiobiolo-

nisms.

gist. We hope that this format will not only be engaging for the

Dr. Newhauser, is Professor and Director of the Medical Physics

readership but will also foster further collaboration in the science

Program at Louisiana State University and Mary Bird Perkins Cancer

and clinical practice of radiation oncology.

Center. His research focus is to improve long‐term health outcomes
of patients with good prospects for survival of a primary cancer. In
particular, his research projects include modeling and measurements

2 | INTRODUCTION

of radiation exposures. He researches risk projection, visualization,
and optimization, and develops methods and prototype systems to

The energy deposition characteristics of protons are substantially dif-

translate these technologies into clinical tools.

ferent from those of conventional radiotherapy beams of photons or

Arguing against the proposition will be Drs. Todd Tenenholz,

electrons. As a result, the use of proton beams for radiotherapy

Yi Rong, and Albert van der Kogel. Dr. Tenenholz is currently the

offers the potential for signiﬁcant improvements in achievable dose

Director of Residency Training at the West Virginia University

distributions.3,4 These differences may result in signiﬁcant improve-

Department of Radiation Oncology. He previously served as the

ments in the efﬁcacy or toxicity proﬁles of radiotherapy for certain

principal pediatric radiation oncologist at Vanderbilt University for

types of cancer. However, such improvements have yet to be

10 yr, and is a member of the Children's Oncology Group.

demonstrated for many treatment sites. In addition, proton therapy

Dr. Rong earned her PhD in Medical Physics at the University of

is substantially more expensive than conventional radiotherapy. As

Wisconsin Madison in 2008. She has been working as a faculty med-

such, an important question becomes “How many proton therapy

ical physicist for 10 yr and is currently an associate professor in the

facilities are necessary in the United States?” There are currently 75

Radiation Oncology department at University of California – Davis.

operational proton therapy facilities worldwide, with 30 of these in

She has also been serving as a reviewer and Associate Editor for

the US alone,5 and additional proton therapy facilities are currently

JACMP for more than 8 yr.

both under construction and under consideration. How many such
facilities do the science and the economics support?

Dr. van der Kogel is professor of clinical radiobiology at the
University of Wisconsin, Madison. His research has focused on

Arguing for the proposition will be Drs. Steve Braunstein, Li

effects of radiation on normal tissues and in particular the spinal

Wang, and Wayne Newhauser. Dr. Braunstein is an academic

cord, as well as on radiation resistance mechanisms related to the
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tumor microenvironment. He is the recipient of the ESTRO Gold

wrong. We have made tremendous advances in cancer treatment

medal and Lifetime Achievement Award, and the ICRU Gray Medal.

outcomes with more than 60% of adults and 80% of children sur-

He is co‐editor of the textbook “Basic Clinical Radiobiology”.

viving their primary cancer for 5 yr or more (this represents a good
surrogate for long‐term disease‐speciﬁc survival). Approximately
two‐thirds of the cost of cancer to society is attributed to disease‐

3 | OPENING STATEMENTS

and treatment‐related morbidity and mortality. Only about one‐third

3.A | Steve Braunstein, MD, PhD; Li Wang, PhD;
Wayne Newhauser, PhD

of the cost goes to direct medical care. Stated in terms of aspirational goals, if we could completely eliminate the morbidity and
mortality of cancer, the savings in avoided morbidity and mortality

Photon beam radiotherapy, including x‐rays and γ‐rays, is the most

would allow a tripling of the direct medical care expenditures. As

widely used type of ionizing radiation in cancer‐directed treatment.

decades of medical research progress has shown, an expensive cure

Proton beam therapy has emerged over the past several decades as

is cheaper than an ineffective treatment. With the continued

a potentially signiﬁcantly improved technological advancement for

advancement in proton delivery technology, leading to decreased

radiotherapy clinical application. Our community of scientists and

capital and operational costs, the capacity to increase the number

evidence‐based practitioners in the United States should build addi-

of facilities can be realized. Moreover, the greater dissemination of

tional proton therapy facilities in order to responsibly develop, care-

proton facilities enables more investigation leading to reﬁnements in

fully study, and properly implement this emerging technology such

treatment planning, delivery techniques including image‐guidance,

that it may deliver on the promise of improved patient care.

and ultimately improved outcomes for select patients. A similar

Based upon its advantageous physical features, proton‐based

precedent was observed with the widespread deployment and sub-

radiotherapy can offer improved dose‐sparing of regional normal tis-

sequent evolution of intensity‐modulated and volumetric arc based

sues while simultaneously allowing for dose‐escalation to the tumor

photon therapy, which ultimately emerged as the most advanced

target.4 This dosimetric advantage is elegantly achieved by the shape

iterations of photon technology. The pace of proton therapy devel-

of the Bragg peak; beyond the end of which the dose falls off very

opment can only be improved with investment in disseminating the

quickly.5 As a result, the exit dose is but a small fraction of that from

technology to more centers.

photon beam therapies. When this basic physical advantage of ﬁnite

Based on the above facts, select patients may potentially beneﬁt

proton range is utilized with algorithmically optimized treatment

more from proton vs photon therapy in the respects of normal tissue

planning methods, then delivered with range and ﬂuence modulation,

protection and superior tumor control. Large‐scale collaborative clini-

it leads to dosimetrically superior treatment plans, particularly in

cal trials and epidemiology studies are needed to determine the role

regions of proximity to uninvolved normal anatomy. Numerous com-

of proton therapy, particularly for children,15 and additional treat-

putational studies have predicted lower risks of second cancers and

ment capacity is needed to accelerate the accrual of outcome data.

other radiogenic late effects in long‐term survivors who receive pro-

The preponderance of available evidence indicates proton therapy is

ton therapy compared with photon therapy.6–11 More generally,

as good as or better than photon therapy for many, but not all,

there is increasing impetus to reduce radiogenic toxicities in normal

patients. To generate a more complete base of outcomes evidence,

tissues,12 a challenging task common to all types of external beam

more proton therapy centers will be needed to conduct multi‐institu-

radiotherapy.

engender

tional clinical trials and long‐term epidemiology studies that compare

increased preservation of the immune compartment leading to

the outcomes of patients who receive proton vs photon treatments.

Decreased

off‐target

dose

may

also

13

improved tumor control.

In the end, expanding proton therapy capacity involves risk and

Notably, the technology to deliver proton therapy is signiﬁcantly

uncertainty; there is no guarantee that the centers will cooperate

distinct from photon‐based delivery and historically has been

and generate much needed evidence. Conversely, based on more

resource‐intensive, limiting widespread manufacture and deployment

than 6 decades of clinical experience, the desired evidence may

of proton delivery facilities. Currently, there are 30 proton centers

never arrive if proton treatment capacity remains at current levels.

in operation, 10 centers are under construction or in development,

Therefore, the United States should build additional proton therapy

and two centers are expanding in the United States.3 Unfortunately,

facilities in more states to deliver on the promise of improved

many of these centers are geographically clustered, limiting access

patient care.

to large segments of the population.14 Most of the contention
regarding further expansion of proton therapy has centered on considerations of absolute cost, cost effectiveness, and related economic considerations. Currently, proton therapy units are the most

3.B | Todd Tenenholz, MD, PhD; Yi Rong, PhD;
Albert van der Kogel, PhD

expensive medical device regulated by the US FDA. Furthermore,

Over the past 12 yr, the United States has seen a dramatic increase

the long‐term ﬁnances of the US health care system are tenuous

in the number of proton therapy centers available to treat patients.

and the aging of the population suggest the potential of increased

In 2006, only four proton centers operated general‐purpose gantries,

utilization. Thus, cost of care is a very legitimate concern. But to

but since then, an additional 26 facilities have opened, with 10 more

neglect the other costs of cancer in this calculation would be

centers under construction or in planning. This remarkable growth

|
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has occurred in a mixture of settings, with some facilities entirely

of the treatment might well have been detected earlier, but would

operated by research‐oriented institutions, while others operate as

likely have signiﬁcantly slowed the adoption of proton therapy. By

partnerships with for‐proﬁt entities. At least nine of these centers

the time these issues came to light, an additional 20 proton facilities

operate as private‐practice entities with no or minimal ties to an

had opened, all treating patients with varying techniques. A compre-

academic research institution. Due to the decentralized nature of

hensive report of the toxicities encountered in this time frame has

the US medical system, all of these centers have developed based

not been published, and general consensus on the solution to the

on local interest, funding, and philanthropy. With no attempt to

problem of RBE in proton therapy does not yet exist, much less has

build a network of centers that would conduct systematic, nation-

been tested widely and made commercially available to private‐prac-

wide investigation into the potential beneﬁts, possible pitfalls, and

tice centers. Is it ethical to continue the expansion of proton therapy

knowledge of the infrastructure (both physical and intellectual)

when fundamental problems such as the ability to predict toxicity

needed to utilize this new technology appropriately, much of the

remain unresolved?

data we now have about proton therapy is based on limited, single

From a hospital's sustainability aspect, proton therapy centers

institution investigations. Few of these studies have direct compar-

are still struggling ﬁnancially. The Scripps Health Proton Cancer

isons between contemporary groups of patients treated with pro-

Therapy Center in San Diego opened in 2014, but ﬁled for bank-

ton vs. photon therapy. This environment has led to a rapid

ruptcy protection in 2017.23 The hope of recouping the initial $220

expansion of proton therapy with very limited evaluation of efﬁ-

million investment by treating 2000 patients per year in the San

cacy, and in some cases, with limited evaluation of even the safety

Diego metropolitan area was never achieved. Instead, only about

of these approaches. Such rapid growth has come at the expense

1400 patients a year have been treated since 2014 according to

of some “growing pains”.

Scripps.24 Most of these patients were treated for prostate cancer.

In 2016, the National Cancer Institute (NCI) convened a national

Even such a large volume of relatively simple cases could not keep

panel to investigate growing concerns about the incidence of brain-

the center operating on “a break‐even basis”. Based on the 2017

stem injury in pediatric patients treated with proton therapy.16 The

American College of Radiation Oncology Billing and Coding Guide,25

growing use of proton therapy as a near mandatory consideration in

25 fractions of proton radiotherapy can only be billed at the same

children with medulloblastoma,17 despite the lack of clinical data,18

amount as 44 fractions of intensity modulated photon therapy

had led to unexpected cases of severe, even fatal brainstem damage.

(IMRT), yet the initial investment for protons is more than ten times

Although ﬁrst reported in 2014,19 the pediatric oncology community

higher than photon therapy. This is due to the lack of evidence that

had been aware of this problem for several years prior to this initial

would demonstrate to insurers and policy experts that protons have

admission of clinical problems with proton therapy. In comparing the

higher effectiveness and better outcome when compared with con-

treatment approaches of the three proton centers with the largest

ventional photon therapy.

pediatric experience, there was a wide range of approaches to treat-

From a physics point of view, we are all aware that the pro-

ment planning even among academic institutions, but all of them

ton's famous “Bragg Peak” is a double‐edged sword. It provides

had calculated effective doses using a ﬁxed relative biological effec-

sharp dose fall off distal from the Bragg Peak, yet at the same

tiveness (RBE) value of 1.1 for protons. However, the concern that

time, it is too sensitive to tumor mobility and patient setup accu-

proton RBE for the central nervous system might be higher than 1.1

racy. Even with stationary tumors and precise patient setup, proton

has recently been conﬁrmed in a comprehensive study in the rat

therapy at its early phase (scanning or scattered beam) has not

spinal cord.20 In this study, the rat cord was irradiated at different

been proven superior to conventional IMRT.26 While the more

positions of the Bragg peak, showing the RBE to increase to 1.2–1.3

advanced intensity modulated proton therapy technique may be

at the distal edge. This ﬁnding fundamentally disproved the previous

associated with reduced toxicity compared to IMRT,27 most

assumption of a ﬁxed and uniform RBE, which suggested potential

reported studies were done in a retrospective fashion, and there is

varying degrees of impact on patients that had been or will be

still a dearth of prospective multicenter randomized trials to vali-

planned with a ﬁxed RBE value of 1.1.

date those reported beneﬁts.

As an interim measure, the guidelines of ACNS0831 were modi-

One may argue that we need more proton centers to start and

ﬁed, essentially allowing dose de‐escalation for patients treated with

participate in those prospective trials. However, there are already

21,22

has suggested that a more

two dozen operating proton therapy centers in the United States,

nuanced (and far more complicated) approach to the problem of

while the enrolled patient numbers on the proton arm of numerous

RBE value in proton therapy planning will be required for clinically

prospective trials are still very low. While there may be other issues

accurate modeling of the effect of proton beam therapy on normal

that are limiting the accrual of patients into prospective trials of pro-

tissues.

ton therapy, the number of proton facilities does not seem to be the

protons. Subsequent literature

What lessons can we glean from this experience? The early problems seen in proton treatment of the posterior fossa in children only

problem, and, adding more proton facilities is unlikely to improve
accrual.

became widely discussed and acknowledged many years after the

Overall, we would argue that the unchecked growth in proton

ﬁrst cohort of patients were treated. If these patients had been trea-

treatment facilities is outstripping the radiation oncology commu-

ted on prospective, dose‐escalation trials, the unanticipated toxicity

nity's ability to properly study, analyze, and use this treatment

10
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modality. A limited number of proton centers, with a primary mission

beyond early phase limited study for proton therapy. No one can

of research, clinical development, and training would be better able

deny that the physics and biology of proton therapy can afford

to deﬁne the appropriate role and scope for proton therapy. Shortly

more conformal radiotherapy treatment with superior avoidance of

after the publication of the NCI consensus opinion, the question of

normal tissue and thus signiﬁcantly mitigated toxicity. We are ready

expanding proton therapy centers was compared to the develop-

to move on to large scale phase III studies, requiring additional pro-

ment of autonomous vehicles28: research and development was not

ton centers for enrollment to exhaustively examine the parameters

being halted because of “early crashes and technical set‐backs”.

for maximum beneﬁt of proton over photon‐based radiotherapy as

Shortly thereafter, such vehicles were placed into “real‐world” use,

well as identify new opportunities for improved outcomes. The

and then promptly withdrawn after they proved unsafe in this set-

upfront costs will be readily offset by gains in reduced costs of

ting. Proton therapy is a powerful tool, but it is clear that we don't

managing late toxicities. The beneﬁts of proton therapy are estab-

fully understand it. It's time to put on the brakes.

lished; we do not need to put on the brakes, but rather move forward in a scientiﬁc, methodical, and cooperative manner to
continue to improve patient outcomes. We owe our patients these

4 | REBUTTAL

efforts and resources.

4.A | Steve Braunstein, MD, PhD; Li Wang, PhD;
Wayne Newhauser, PhD
We appreciate our colleagues’ thoughtful position against building

4.B | Todd Tenenholz, MD, PhD; Yi Rong, PhD;
Albert van der Kogel, PhD

additional proton radiotherapy facilities. However, while it is true

Our colleagues have argued that expanding the number of US pro-

that upfront capital costs of proton facilities are signiﬁcant in com-

ton therapy centers will lead to increased patient access and effec-

parison to photon‐based technologies, that cost is decreasing, albeit

tiveness research, and that the direct costs of such expansion are

slowly, with an increasing number of vendors supporting cost‐cutting

small related to the overall costs of patient care. Unfortunately,

technological developments in proton therapy.29 In addition, though

while the US has led the world in the adoption of expensive treat-

several of the initial proton centers were funded with high proﬁt‐

ment technologies and paradigms, the return on this investment in

margin expectations, current health care economics have led to

terms of actual health outcomes has been disappointing relative to

adjusted expectations such that future proton facilities are being

other industrialized, English‐speaking countries.33 In fact, a great deal

developed thoughtfully for the current climate, including design of

of this cost has been transferred to our patients, with over half of

smaller facilities and with community partnerships to ensure sustain-

US patients diagnosed with a serious medical condition reporting

ability. Importantly, comparisons of true cost‐effectiveness should

severe ﬁnancial hardship as a result.34 Even if we accept the premise

consider not only the cost of treatment of the primary cancer, but

that “an expensive cure is cheaper than an ineffective treatment”,

also the actual or estimated costs of late toxicities, which are lower

there is little evidence, or even theoretical speculation, that protons

with advanced radiotherapy technologies like proton therapy.30,31

will be more effective than photons from a cancer control perspec-

Thus, the economic gain of proton therapy will be realized with

tive. While our colleagues may argue that the decrease in late

long‐term follow‐up.

effects promised by protons may justify their cost, the current rapid

It has taken decades to rigorously study the appropriate parame-

expansion of proton therapy has not resulted in increased research

ters for optimum photon‐based radiotherapy delivery, with many

to establish this argument. As an example, despite enrollment of 437

clinical, biological, and technical issues still unresolved. The chal-

proton therapy eligible patients in ACNS 0831, only 135 of these

lenges of assessing value with deployment of advanced technologies

patients have been enrolled in the ALET07C1 companion study of

in radiation oncology, such as protons, are well‐recognized and

neuropsychological outcomes.35 This is not a failure of patient

32

require a concerted effort of the community to properly study.

access, it is a failure of the treating physicians to prioritize outcomes

Once value is recognized, broader insurance coverage may follow.

research.

Such a herculean effort is only afforded by large‐scale cooperative

While there are important arguments to be made regarding the

registries and networks of treatment centers of study, demonstrated

reduction of second primary cancers in the pediatric population, such

by the NRG, Alliance, SWOG, and ECOG groups. Large cooperative

patients constitute a small minority of patients treated with radiother-

group studies with focus on proton therapy are emerging but ulti-

apy in the US. While the population of adult 5 yr cancer survivors is

mately require more centers to achieve the needed accrual rates. As

growing, these are predominantly patients treated for prostate and

noted in the opposition statement, the recent effort of an NCI work-

breast cancer. The incidence of secondary malignancy in such

ing group addressing the uncertainties in proton therapy RBE and

patients appears to be low in the former,36 and has likely been over-

subsequent structured recommendations to minimize radionecrosis

estimated in the latter.37,38 Such arguments hardly justify recent

risk justify the additional centers to participate in these and other

reports of proton therapy for treating small cell lung, pancreatic, and

collaborative efforts.

esophageal cancers.39–41 In fact, the dose limiting toxicities for many

Ultimately, we must acknowledge radiation as an empirical

adult malignancies relate to tissues in close proximity to the target

science. After decades of implementation, we are ready to move

volume, a situation in which protons may have little dosimetric

|
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Steve Braunstein1*

advantage compared to other treatments, due to high dosimetric sen42

Li Wang2*

sitivity to internal tumor/organ motion and anatomy change.

In addition to this theoretical advantage of a reduced risk of sec-

Wayne Newhauser3*

ondary malignancies, the key argument for the use of protons has

Todd Tenenholz4*

been the steep dose fall off beyond the Bragg peak, thus conferring

Yi Rong5*

an advantage when treating tumors close to critical normal tissues.

Albert van der Kogel6*

As we mentioned in the opening statement, the generally accepted

Michael Dominello7

RBE of 1.1 for proton dose delivered in normal tissues has been

Michael C. Joiner7
Jay Burmeister7,8

challenged by the recent rat spinal cord study with a 10% or more
increase at the distal edge of the Bragg peak. These uncertainties

Department of Radiation Oncology, University of California – San

1

emphasize the need for (pre)clinical studies of normal tissue toler-

Francisco, San Francisco, CA, USA; 2Department of Radiation Oncology,

ance that so far have been lacking. Therefore, the combined impact

University of Texas – MD Anderson Cancer Center, Houston, TX, USA;

of dosimetric and radiobiological uncertainties may diminish the
claimed beneﬁts of critical organ sparing by proton therapy for various cancer sites.

3

Department of Physics and Astronomy, Louisiana State University,
Baton Rouge, LA, USA; 4Department of Radiation Oncology, West

Virginia University, Morgantown, WV, USA; 5Department of Radiation

Our colleagues further offered IMRT and VMAT as an analogy to

Oncology, University of California – Davis Cancer Center, Sacramento,

proton therapy and argued that as more centers adopt this technol-

CA, USA; 6Department of Human Oncology, University of Wisconsin,

ogy, its value will become obvious. However, the well‐established

Madison, WI, USA; 7Department of Oncology, Wayne State University

improvement in dosimetric conformity of IMRT over conventional

School of Medicine, Detroit, MI, USA 8Gershenson Radiation Oncology

3D‐CRT planning came at a relatively modest ﬁnancial cost in the

Center, Barbara Ann Karmanos Cancer Institute, Detroit, MI, USA

range of 1 million dollars per gantry. VMAT offers a signiﬁcant, practical advantage of shortened treatment delivery time at even less
cost in upgrading the software and hardware. For these reasons,
both practitioners and insurers were willing to adopt these evolutions of existing technology based on predicted dosimetric improve-

Author to whom correspondence should be addressed.
Jay Burmeister
Email: burmeist@karmanos.org; Telephone: (313) 576 9617
*The ﬁrst six authors contributed equally to this work.

ments. The dosimetric improvement and potential impact on
outcome promised by proton therapy is mostly applicable to a limited population of patients, but the cost of building a proton center
is in the range of $100–$200 million dollars.
The current geographic clustering of proton therapy centers is
driven by the same market‐driven factors that have led the cost of
US healthcare to vastly outpace its improvement in outcomes. The
closure of the Indiana University and Scripps proton centers due to
ﬁnancial infeasibility, despite their locations in areas that should have
improved accessibility for large populations, highlights the burden
that the extreme cost of proton therapy places on the healthcare
system and patients. The problem is not access, it is cost. For about
$1 million, a cohort of 120 patients eligible for clinical investigation
of proton therapy could be given transportation and lodging for the
duration of their radiation treatment. This would be far more effective in terms of accomplishing actual clinical research, and orders of
magnitude less costly than the construction of a single additional
proton facility. Adopting a more “St Jude's” like model for conducting
proton therapy research would help to identify the patients who
would truly beneﬁt from this new modality, and would likely do so
with higher quality data and much lower overall cost than construction of additional proton centers.
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